Neuphoria Therapeutics Inc. - Common Stock (NEUP) Competitors $5.72 -0.08 (-1.38%) As of 03/28/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrendsBuy This Stock NEUP vs. ALXO, OSTX, XCUR, ESLA, INKT, TPST, NRXP, RVPH, CASI, and CVKDShould you be buying Neuphoria Therapeutics Inc. - Common Stock stock or one of its competitors? The main competitors of Neuphoria Therapeutics Inc. - Common Stock include ALX Oncology (ALXO), OS Therapies (OSTX), Exicure (XCUR), Estrella Immunopharma (ESLA), MiNK Therapeutics (INKT), Tempest Therapeutics (TPST), NRx Pharmaceuticals (NRXP), Reviva Pharmaceuticals (RVPH), CASI Pharmaceuticals (CASI), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical products" industry. Neuphoria Therapeutics Inc. - Common Stock vs. ALX Oncology OS Therapies Exicure Estrella Immunopharma MiNK Therapeutics Tempest Therapeutics NRx Pharmaceuticals Reviva Pharmaceuticals CASI Pharmaceuticals Cadrenal Therapeutics ALX Oncology (NASDAQ:ALXO) and Neuphoria Therapeutics Inc. - Common Stock (NASDAQ:NEUP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings. Do analysts rate ALXO or NEUP? ALX Oncology currently has a consensus target price of $4.14, suggesting a potential upside of 531.96%. Neuphoria Therapeutics Inc. - Common Stock has a consensus target price of $21.00, suggesting a potential upside of 267.13%. Given ALX Oncology's higher possible upside, analysts clearly believe ALX Oncology is more favorable than Neuphoria Therapeutics Inc. - Common Stock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Neuphoria Therapeutics Inc. - Common Stock 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, ALXO or NEUP? ALX Oncology has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Neuphoria Therapeutics Inc. - Common Stock has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Which has better earnings and valuation, ALXO or NEUP? Neuphoria Therapeutics Inc. - Common Stock has higher revenue and earnings than ALX Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$160.80M-$2.60-0.25Neuphoria Therapeutics Inc. - Common Stock$662.72K15.16-$15.49MN/AN/A Does the MarketBeat Community believe in ALXO or NEUP? ALX Oncology received 54 more outperform votes than Neuphoria Therapeutics Inc. - Common Stock when rated by MarketBeat users. However, 100.00% of users gave Neuphoria Therapeutics Inc. - Common Stock an outperform vote while only 64.71% of users gave ALX Oncology an outperform vote. CompanyUnderperformOutperformALX OncologyOutperform Votes5564.71% Underperform Votes3035.29% Neuphoria Therapeutics Inc. - Common StockOutperform Votes1100.00% Underperform VotesNo Votes Is ALXO or NEUP more profitable? Neuphoria Therapeutics Inc. - Common Stock's return on equity of 0.00% beat ALX Oncology's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -93.02% -70.67% Neuphoria Therapeutics Inc. - Common Stock N/A N/A N/A Do insiders and institutionals have more ownership in ALXO or NEUP? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics Inc. - Common Stock shares are held by institutional investors. 33.4% of ALX Oncology shares are held by company insiders. Comparatively, 0.7% of Neuphoria Therapeutics Inc. - Common Stock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor ALXO or NEUP? In the previous week, ALX Oncology had 2 more articles in the media than Neuphoria Therapeutics Inc. - Common Stock. MarketBeat recorded 3 mentions for ALX Oncology and 1 mentions for Neuphoria Therapeutics Inc. - Common Stock. Neuphoria Therapeutics Inc. - Common Stock's average media sentiment score of 1.87 beat ALX Oncology's score of 0.97 indicating that Neuphoria Therapeutics Inc. - Common Stock is being referred to more favorably in the news media. Company Overall Sentiment ALX Oncology Positive Neuphoria Therapeutics Inc. - Common Stock Very Positive SummaryALX Oncology and Neuphoria Therapeutics Inc. - Common Stock tied by winning 7 of the 14 factors compared between the two stocks. Remove Ads Get Neuphoria Therapeutics Inc. - Common Stock News Delivered to You Automatically Sign up to receive the latest news and ratings for NEUP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEUP vs. The Competition Export to ExcelMetricNeuphoria Therapeutics Inc. - Common StockPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.05M$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E RatioN/A7.1723.3318.67Price / Sales15.16220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book0.736.396.894.23Net Income-$15.49M$142.12M$3.20B$247.15M7 Day Performance6.32%-5.06%-2.98%-2.17%1 Month Performance10.00%-7.49%1.63%-5.68%1 Year PerformanceN/A-10.91%9.45%-0.74% Neuphoria Therapeutics Inc. - Common Stock Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEUPNeuphoria Therapeutics Inc. - Common Stock1.9657 of 5 stars$5.72-1.4%$21.00+267.1%N/A$10.05M$662,715.000.00N/APositive NewsGap UpALXOALX Oncology3.8654 of 5 stars$0.71-5.5%$4.14+485.5%-94.1%$37.75MN/A-0.2440OSTXOS Therapies2.3871 of 5 stars$1.73+8.8%$17.50+911.6%N/A$37.65MN/A0.00N/AXCURExicure1.2439 of 5 stars$14.05+3.6%N/A+2,225.9%$36.61M$500,000.00-6.7950Short Interest ↑News CoverageGap DownESLAEstrella Immunopharma2.4568 of 5 stars$1.01+9.6%$16.00+1,484.2%-23.5%$36.54MN/A-3.88N/APositive NewsINKTMiNK Therapeutics2.4188 of 5 stars$9.10+8.2%$37.50+312.1%-0.6%$36.09MN/A-2.3330TPSTTempest Therapeutics2.7911 of 5 stars$0.82+1.4%$26.00+3,063.8%-80.3%$35.87MN/A-0.5420Earnings ReportUpcoming EarningsAnalyst ForecastShort Interest ↓News CoverageGap DownNRXPNRx Pharmaceuticals2.5886 of 5 stars$2.08+0.5%$31.67+1,422.4%-95.7%$35.19MN/A-0.972RVPHReviva Pharmaceuticals4.2174 of 5 stars$1.04-5.5%$11.40+996.2%-73.3%$34.78MN/A-0.945Short Interest ↓Gap UpCASICASI Pharmaceuticals4.3261 of 5 stars$2.23-2.9%$6.00+168.6%-40.3%$34.61M$22.06M-1.00180Analyst ForecastShort Interest ↓Positive NewsCVKDCadrenal Therapeutics2.5734 of 5 stars$19.37-0.7%$32.00+65.2%N/A$34.54MN/A-2.904Short Interest ↑ Remove Ads Related Companies and Tools Related Companies ALXO Competitors OSTX Competitors XCUR Competitors ESLA Competitors INKT Competitors TPST Competitors NRXP Competitors RVPH Competitors CASI Competitors CVKD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEUP) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. - Common Stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics Inc. - Common Stock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NEUP Stock Free NEUP Stock Alerts